Name: PYC Therapeutics (PYC) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

PYC

Pharmaceuticals, Biotechnology & Life Sciences

PYC Therapeutics

Short interest: 0.79%; +0.78 pp 30d; as of 8 Oct 2026
Reported shorts: 7.8M
Shares on issue: 983.510M

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About PYC Therapeutics

PYC Therapeutics is a clinical-stage biotech company focused on developing RNA therapies to address genetic diseases. Their proprietary RNA delivery platform aims to provide safer and more effective treatments by targeting the underlying causes of these diseases. The company is advancing a pipeline of novel therapies for eye, central nervous system, and kidney diseases.

Company profile →

PYC Therapeutics (ASX:PYC) has 0.79% of its shares on issue reported as short positions as of 8 Oct 2026, or about 7,765,234 shares. Over the past 30 days that figure has risen 0.78 percentage points, and over 90 days it has risen 0.45 percentage points. Its highest recorded short interest was 1.09% in September 2026. PYC is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads PYC today

Zanger BreakoutWatchScore 38rank 262 of 1942
CAN SLIMWatchScore 33rank 268 of 1541
Minervini Trend TemplateSetupScore 59rank 106 of 1716
Crowded-Short BreakoutWatchScore 25rank 186 of 1502
Quality compoundersWatchScore 49rank 126 of 1669

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

PYC fundamentals

In the year to 30 Jun 2026, PYC Therapeutics (ASX:PYC) recorded revenue of A$39.7M and a net loss after tax of A$43.3M. A year earlier it recorded revenue of A$26.2M and a net loss after tax of A$50.3M. Year-on-year growth: revenue +51.6% (FY). Net margin −109.2%, return on equity −10.0% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →